The pathology of familial breast cancer: Immunohistochemistry and molecular analysis

Extensive studies of BRCA1- and BRCA2-associated breast tumours have been carried out in the few years since the identification of these familial breast cancer predisposing genes. The morphological studies suggest that BRCA1 tumours differ from BRCA2 tumours and from sporadic breast cancers. Recent progress in immunohistochemistry and molecular biology techniques has enabled in-depth investigation of molecular pathology of these tumours. Studies to date have investigated issues such as steroid hormone receptor expression, mutation status of tumour suppressor genes TP53 and c-erbB2, and expression profiles of cell cycle proteins p21, p27 and cyclin D1. Despite relative paucity of data, strong evidence of unique biological characteristics of BRCA1-associated breast cancer is accumulating. BRCA1-associated tumours appear to show an increased frequency of TP53 mutations, frequent p53 protein stabilization and absence of imunoreactivity for steroid hormone receptors. Further studies of larger number of samples of both BRCA1- and BRCA2-associated tumours are necessary to clarify and confirm these observations.

[1]  M. Loda,et al.  The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. , 1997, Cancer research.

[2]  D. Miles,et al.  Family history and survival in premenopausal breast cancer. , 1998, British Journal of Cancer.

[3]  Å. Borg,et al.  Tumour biological features of BRCA1-induced breast and ovarian cancer. , 1997, European journal of cancer.

[4]  L. Norton,et al.  BRCA-associated breast cancer in young women. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  R. Peto,et al.  Variation in use of adjuvant tamoxifen , 1998, The Lancet.

[6]  I. Ellis,et al.  p21(WAF1) expression and endocrine response in breast cancer. , 1999, The Journal of pathology.

[7]  J. Peto,et al.  Predicted anti-oestrogen resistance in BRCA-associated familial breast cancers. , 1998, European journal of cancer.

[8]  M. Ewen,et al.  P/CAF associates with cyclin D1 and potentiates its activation of the estrogen receptor. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[9]  M. Duffy,et al.  Proteases as prognostic markers in cancer. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  M. Stratton,et al.  Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. , 1998, Journal of the National Cancer Institute.

[11]  G. Berx,et al.  E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. , 1996, Oncogene.

[12]  D. Barnes,et al.  Cyclin D1 and associated proteins in mammary ductal carcinoma in situ and atypical ductal hyperplasia , 1998, The Journal of pathology.

[13]  C. Markopoulos,et al.  Expression of pS2 protein and estrogen and progesterone receptor status in breast cancer. , 1997, Acta Cytologica.

[14]  M. J. van de Vijver,et al.  Simultaneous loss of E‐cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ , 1997, The Journal of pathology.

[15]  R. Fulco,et al.  Prognostic significance of the estrogen-regulated proteins, cathepsin-D and pS2, in breast cancer. , 1998, Minerva medica.

[16]  G. Giles,et al.  Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study. , 1999, Cancer research.

[17]  M. Ewen,et al.  Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4 , 1997, Molecular and cellular biology.

[18]  M. Fernö,et al.  Correlation between p53, c‐erbB‐2, and topoisomerase IIα expression, DNA ploidy, hormonal receptor status and proliferation in 356 node‐negative breast carcinomas: prognostic implications , 1999, The Journal of pathology.

[19]  J. Peto,et al.  p53 mutation with frequent novel codons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours , 1998, Oncogene.

[20]  Anthony E. Reeve,et al.  E-cadherin germline mutations in familial gastric cancer , 1998, Nature.

[21]  J. Fletcher,et al.  HER-2/neu (c-erb-B2) gene and protein in breast cancer. , 1999, American journal of clinical pathology.

[22]  I. Ellis,et al.  p21WAF1 expression and endocrine response in breast cancer , 1999 .

[23]  T. Powles,et al.  Hormone status of in-situ cancer in BRCA1 and BRCA2 mutation carriers , 1998, The Lancet.

[24]  L. Norton,et al.  BRCA-associated breast cancer: absence of a characteristic immunophenotype. , 1998, Cancer research.

[25]  B. Gusterson,et al.  Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions , 1999, Oncogene.

[26]  Fernández,et al.  Cathepsin D in host stromal cells is associated with more highly vascular and aggressive invasive breast carcinoma , 1999, Histopathology.

[27]  M. Stratton.  Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases , 1997, The Lancet.

[28]  Yi-Song Wang,et al.  WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. , 1994, Cancer research.

[29]  B. Gusterson,et al.  p53 mutations in BRCA1-associated familial breast cancer , 1997, The Lancet.

[30]  H. Rochefort,et al.  Cathepsin D in cancer metastasis: A protease and a ligand , 1999, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.